Lana Pine

While nipocalimab is under consideration as the first marketed drug for HDFN, clinicians consider the importance of awareness and dedicated research into the rare disease.

Compared with other bDMARDs, patients with rheumatoid arthritis treated with tofacitinib had a 4-fold reduced incidence of interstitial lung disease.

Upadacitinib, a selective and reversible Janus kinase (JAK) inhibitor, may be a promising treatment option for patients with systemic lupus erythematosus.

SEL-212, an alternative to standard therapy that is administered once monthly, has proven to be particularly helpful for patients with severe gout, a historically underserved population.

No significant budget increase was observed in patients with non-radiographic axial spondyloarthritis (nr-axSpA) receiving secukinumab.

An analysis of perimenopausal women with rheumatoid arthritis indicated that patients receiving exogenous sex hormones more frequently achieved SDAI- and CDAI-defined remission.

Statistical analysis showed no differences between each pairwise comparison of the bevacizumab biosimilars, MB02-SP and MB02-DM, and the reference drug.

Bruce Feinberg, DO, explained that he and his team at Cardinal Health are constantly examining the market and the various influences that impact biosimilar uptake.

The approval was based on positive results from the phase I pharmacokinetics bridging study, which showed comparable PK and similar safety and immunogenicity of adalimumab 50 mg/mL and adalimumab high-concentration formulation.

Bruce Feinberg, DO, noted that although patients and providers ultimately understand that a biosimilar should theoretically be just as effective as a biologic, prescribers may still be wary of switching patients to a different product when they have historically experienced an excellent response to the original treatment.

Bruce Feinberg, DO, explained how Cardinal Health used its 2023 Biosimilars Report to better understand the provider's insight on industry changes that are occurring due to the expansion of biosimilars.

Often overlooked and underfunded, as well as being underpaid compared to internal medicine, it is difficult to convince prospective medical students, many of whom already have substantial debt, to choose a career in pediatric rheumatology.

The phase 3 DISCOVER-1 and DISCOVER-2 studies were used to evaluate dactylitis resolution in guselkumab-treated patients with psoriatic arthritis through 1 year.

Polypharmacy, defined as ≥5 concomitant drugs, was significantly higher in patients with psoriatic arthritis when compared with controls (49% vs 17%, respectively).

Adult patients with traumatic brain injury-induced fibromyalgia were randomized 1:1 to receive hyperbaric oxygen therapy or pharmacological intervention.

No sign of harmful impacts related to the mandatory biosimilar switching policy for patients with inflammatory bowel diseases treated with infliximab was observed in the cohort study.

A recent study found no association between exposure to rituximab biosimilars and hospitalization for hypersensitivity reactions compared to the biologic at initiation, at switch, or over time.

A significant decrease in indirect costs was observed in patients switching from intravenous to subcutaneous CT-P13, which was attributed to lower total costs overall.

Results demonstrate that guselkumab was well-tolerated in studies continuing for 1 to 2 years among patients with active psoriatic arthritis regardless of TNFi experience.

No differences in adverse events, including infusion-related reactions, infections, and hypogammaglobulinemia, were reported among patients receiving rituximab and the biosimilar, CT-P10.

Dialysis-dependent patients in the US with gout have an increased risk of cardiovascular comorbidities, hospitalization, and mortality. Results emphasize the need for improved treatments to enhance outcomes for this patient population.

Although etanercept biosimilars demonstrated comparable efficacy, safety, and immunogenicity when compared with the reference drug, biosimilar treatment was associated with a better ACR50 response rate.

Disease activity and burden were higher in patients with rheumatoid arthritis with Medicaid or Medicare coverage, African American patients, and those residing in Southern regions.

A brief increase in venous thromboembolism (VTE) was reported within 30 days after a hospitalization or primary care visit for gout flare. The highest incidence occurred during the 16-30 day period after the flare.

Radiographic non-progressors treated with guselkumab achieved patient-reported minimal disease activity criteria of minimal pain and normalized physical function more often than radiographic non-responders.

Compared with the control group, patients in the exercise for wellbeing (Qi Gong) and physiotherapy groups reported statistically significant improvements at week 5 in joint range of movement, muscle strength, spirometry, and quality of life.

Improvements may be due in part to the association between weight loss and fewer pain symptoms in patients with fibromyalgia.

The approval was based on positive results from the Phase 3 SAPHYR trial, which showed that nearly 3 times more patients achieved sustained remission with sarilumab when compared with placebo.

Results of a recent review showed that adalimumab, etanercept, golimumab, and infliximab are effective and well-tolerated treatments options for patients with juvenile idiopathic arthritis.

Nipocalimab, a FcRn blocker, significantly improved symptoms and reduced immunoglobulin autoantibody levels in patients with myasthenia gravis.